Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance
CNBC - 2024-05-07T15:33:29.000Z

Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are progressing on their own treatments.

In related news

Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supply
Eli Lilly and Novo Nordisk are boosting supply of their weight loss drugs, while Apple Watch's heart-monitoring tech was approved for use in clinical studies.
- Related Articles
- In News
- From CNBC
- 2024-05-07T19:15:25.000Z
How weight loss drugs like Wegovy are transforming the weight loss industry
Since weight loss drugs have come online, the weight loss industry has ballooned from about $76 billion a year to almost $90 billion in 2023.
- Related Articles
- In News
- From @Marketplace
- 2024-05-09T13:53:13.000Z
People on Novo Nordisk's Wegovy maintain weight loss for up to four years, study says
The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to cover the costly drug.
- Related Articles
- In News
- From CNBC
- 2024-05-14T14:12:48.000Z